Dabigatran for stroke prevention in atrial fibrillation: The RE-LY trial

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 3, 2011, Pages 279-286

  Paikin, Jeremy S ^a   Haroun, Michelle J ^a   Eikelboom, John W ^a  

^a HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

anticoagulation; atrial fibrillation; dabigatran; stroke; warfarin

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; DABIGATRAN ETEXILATE; KETOCONAZOLE; QUINIDINE; RIFAMPICIN; VERAPAMIL; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; CANADA; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG HALF LIFE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; EMBOLISM; FOLLOW-UP STUDIES; HUMANS; PROSPECTIVE STUDIES; PYRIDINES; RISK FACTORS; STROKE; VITAMIN K; WARFARIN;

EID: 79953245459     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.21     Document Type: Article

References (22)

1. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285, 2370-2375 (2001). (Pubitemid 32424106)
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007). Meta-analysis demonstrating the relative efficacy of antiplatelet and anticoagulant medications in thromboprophylaxis of stroke in patients with nonvalvular atrial fibrillation. (Pubitemid 351650486)
3. Hirsh J. Oral anticoagulant drugs. N. Engl. J. Med. 324, 1865-1875 (1991). Landmark review of oral anticoagulants.
4. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann. Intern. Med. 131(12), 927-934 (1999). (Pubitemid 30005032)
5. Waldo AL, Becker RC, Tapson VF, Colgan KJ; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J. Am. Coll. Cardiol. 46, 1729-1736 (2005). (Pubitemid 41531631)
6. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: Results of the veterans affairs study to improve anticoagulation (VARIA). Circ. Cardiovasc. Qual. Outcomes 4(1), 22-29 (2011).
7. Connolly S, Pogue J, Hart R et al.; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial Fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 367, 1903-1912 (2006). Demonstrated the superiority of warfarin compared with dual antiplatelet therapy in the prevention of stroke in patients with atrial fibrillation.
8. Connolly SJ, Pogue J, Eikelboom J et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118, 2029-2037 (2008).
9. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet. 47, 285-295 (2008). (Pubitemid 351508116)
10. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009).
11. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized evaluation of long-term anticoagulation therapy investigators. Newly identified events in the RE-LY trial. N. Engl. J. Med. 363(19), 1875-1876 (2010). Newly identified events found after the original publication of the Randomized Evaluation of Long-Term Anticoagulation (RE-LY) trial.
12. Ezekowitz MD, Connolly S, Parekh A et al. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am. Heart J. 157(5), 805-810 (2009).
13. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann. Intern. Med. 131, 492-501 (1999). (Pubitemid 29482392)
14. Ezekowitz MD, Wallentin L, Connolly SJ et al. Dabigatran and warfarin in vitamin K antagonist naive and experienced cohorts with atrial fibrillation. Circulation 122, 2246-2253 (2010).
15. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 376, 975-983 (2010). Describes the consistent benefits of dabigatran etexilate irrespective of international normalized ratio control.
16. Diener HC, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial. Lancet Neurol. 9, 1157-1163 (2010).
17. Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion. Circulation 123(2), 131-136 (2011).
18. Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am. J. Med. 123(9), 785-789 (2010).
19. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: A meta-analysis of randomized trials. Arch. Intern. Med. 167, 117-124 (2007). (Pubitemid 46148058)
20. Freeman JV, Zhu RP, Owens DK et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann. Intern. Med. 154(1), 1-11 (2011).
21. Ufer M. Comparative pharmacokinetics of vitamin K antagonists. Clin. Pharmacokinet. 44(12), 1227-1246 (2005).
22. Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol. 9(3), 273-284 (2010).